Results 171 to 180 of about 54,385 (262)

Management of Advanced Prostate Cancer in the Asia‐Pacific Region: Summary of the Asia‐Pacific Advanced Prostate Cancer Symposium 2025

open access: yesAsia-Pacific Journal of Clinical Oncology, Volume 22, Issue 4, Page 546-556, August 2026.
Summary of the Asia Pacific Advanced Prostate Cancer Symposium 2025, showing disciplines and diversity of participants, discussion topics (high‐risk localized/locally advanced prostate cancer; PSA persistence and recurrence; radioligand therapy; genetics and genomics; bone protection and other aspects of supportive care), key themes, and high‐level ...
Edmund Chiong   +28 more
wiley   +1 more source

Concurrent Hashimoto's Encephalopathy and Papillary Thyroid Carcinoma: A Case Report

open access: yesClinical and Experimental Neuroimmunology, Volume 17, Issue 3, August 2026.
ABSTRACT Background Hashimoto's encephalopathy (HE) is a rare steroid‐responsive autoimmune syndrome. Although HE is associated with anti‐thyroid antibodies, its concurrence with malignant thyroid tumors has rarely been described and its clinical implications remain poorly understood.
Ryo Hara   +12 more
wiley   +1 more source

Is three-phase bone scintigraphy really obsolete? : a combined TPBS-CRP diagnostic method. [PDF]

open access: yesBone Joint Res
Chen Q   +7 more
europepmc   +1 more source

[18F]PSMA‐1007 PET–Based Recurrence Site Distribution and Predictors of Metastatic Disease in Patients With Biochemical Recurrence of Prostate Cancer

open access: yesInternational Journal of Urology, Volume 33, Issue 8, August 2026.
ABSTRACT Objectives Prostate‐specific membrane antigen positron emission tomography (PSMA‐PET) is a sensitive imaging modality for detecting recurrent prostate cancer following definitive local therapy. However, evidence on 18F‐labeled PSMA tracers in Japanese patients with biochemical recurrence (BCR) remains limited.
Koji Hatano   +15 more
wiley   +1 more source

Parathyroid carcinoma diagnosed after pulmonary metastases 8 years after initial parathyroidectomy. [PDF]

open access: yesJCEM Case Rep
Matsuda N   +5 more
europepmc   +1 more source

Real‐World Outcomes of Radium‐223 Therapy in Metastatic Castration‐Resistant Prostate Cancer: Predictive Value of PSA Doubling Time and Enzalutamide Continuation

open access: yesInternational Journal of Urology, Volume 33, Issue 8, August 2026.
ABSTRACT Background Radium‐223 dichloride (Ra‐223) is an effective treatment for metastatic castration‐resistant prostate cancer (mCRPC) with bone metastases. However, predictive factors associated with treatment efficacy remain unclear. This study evaluated prognostic factors associated with the efficacy of Ra‐223 and investigated outcomes according ...
Kodai Abe   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy